Literature DB >> 31385027

Invasive stratified mucin-producing carcinoma (i-SMILE) of the uterine cervix: report of a case series and review of the literature indicating poor prognostic subtype of cervical adenocarcinoma.

Lars-Christian Horn1, Romy Handzel2, Gudrun Borte3, Udo Siebolts4, Anja Haak4, Christine E Brambs5.   

Abstract

PURPOSE: Invasive stratified mucin-producing carcinoma (i-SMILE) represents a recently recognized subtype of cervical adenocarcinoma (AC) developing in a background of a stratified mucin-producing intraepithelial lesion (SMILE). Clinical and prognostic data on i-SMILE are limited.
METHODS: We report a series of five cases with histopathological, immunohistochemical (p16) and PCR analyses. The cases as well as the patients previously published in the literature were reviewed for follow-up information.
RESULTS: Thirteen cases were identified. The mean age of 47.1 years (range 34-66) was not different from the usual type of cervical AC. 10/13 cases presented with tumors > 2 cm and a polypoid-exophytic appearance. Regardless of tumor size and stage of the disease, 7 out of 11 patients developed recurrent disease after a mean of 7.8 months (range 6 weeks-36 months). Five patients developed distant metastases (three of them in the lungs). Five out of the 11 informative cases died of the disease. All reported cases were positive for high-risk HPV (mainly HPV type 18) and associated with p16-overexpression.
CONCLUSION: i-SMILE represent a distinct subtype of invasive endocervical AC, associated high-risk HPV infection and strong p16-overexpression. Clinically, i-SMILE may represent an aggressive tumor with early recurrent disease and substantial risk of distant metastatic disease, especially to the lungs.

Entities:  

Keywords:  Adenocarcinoma; Cancer; Cervix; HPV; Invasive; Prognosis; SMILE; Stratified mucin-producing carcinoma; TMMR; p16

Mesh:

Substances:

Year:  2019        PMID: 31385027     DOI: 10.1007/s00432-019-02991-3

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  26 in total

1.  Gastric-type Endocervical Adenocarcinoma: An Aggressive Tumor With Unusual Metastatic Patterns and Poor Prognosis.

Authors:  Yevgeniy S Karamurzin; Takako Kiyokawa; Vinita Parkash; Anjali R Jotwani; Prusha Patel; Malcolm C Pike; Robert A Soslow; Kay J Park
Journal:  Am J Surg Pathol       Date:  2015-11       Impact factor: 6.394

2.  Mixed small cell carcinomas of the uterine cervix: prognostic impact of focal neuroendocrine differentiation but not of Ki-67 labeling index.

Authors:  Lars-Christian Horn; Bettina Hentschel; Karl Bilek; Christine E Richter; Jens Einenkel; Cornelia Leo
Journal:  Ann Diagn Pathol       Date:  2006-06       Impact factor: 2.090

3.  Stratified mucin-producing intraepithelial lesion (SMILE): report of a case series with associated pathological findings.

Authors:  David P Boyle; W Glenn McCluggage
Journal:  Histopathology       Date:  2015-01-15       Impact factor: 5.087

4.  Pattern analysis of regional spread and therapeutic lymph node dissection in cervical cancer based on ontogenetic anatomy.

Authors:  Michael Höckel; Lars-Christian Horn; Elisabeth Tetsch; Jens Einenkel
Journal:  Gynecol Oncol       Date:  2011-12-08       Impact factor: 5.482

5.  Neuroendocrine Carcinoma of the Cervix: Review of a Series of Cases and Correlation With Outcome.

Authors:  Raji Ganesan; Lynn Hirschowitz; Philip Dawson; Sarah Askew; Philippa Pearmain; Peter W Jones; Kavita Singh; Kiong K Chan; Esther L Moss
Journal:  Int J Surg Pathol       Date:  2016-04-20       Impact factor: 1.271

6.  Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix.

Authors:  Atsumi Kojima; Yoshiki Mikami; Tamotsu Sudo; Satoshi Yamaguchi; Yasuki Kusanagi; Masaharu Ito; Ryuichiro Nishimura
Journal:  Am J Surg Pathol       Date:  2007-05       Impact factor: 6.394

7.  Prognostic factors in adenocarcinoma of the uterine cervix.

Authors:  A Baalbergen; P C Ewing-Graham; W C J Hop; P Struijk; Th J M Helmerhorst
Journal:  Gynecol Oncol       Date:  2004-01       Impact factor: 5.482

8.  Resection of the embryologically defined uterovaginal (Müllerian) compartment and pelvic control in patients with cervical cancer: a prospective analysis.

Authors:  Michael Höckel; Lars-Christian Horn; Norma Manthey; Ulf-Dietrich Braumann; Ulrich Wolf; Gero Teichmann; Katrin Frauenschläger; Nadja Dornhöfer; Jens Einenkel
Journal:  Lancet Oncol       Date:  2009-05-29       Impact factor: 41.316

9.  Adenoma malignum (minimal deviation adenocarcinoma) of the uterine cervix. A clinicopathological and immunohistochemical analysis of 26 cases.

Authors:  C B Gilks; R H Young; P Aguirre; R A DeLellis; R E Scully
Journal:  Am J Surg Pathol       Date:  1989-09       Impact factor: 6.394

10.  Laterally extended endopelvic resection (LEER)--principles and practice.

Authors:  Michael Höckel
Journal:  Gynecol Oncol       Date:  2008-08-23       Impact factor: 5.482

View more
  9 in total

Review 1.  [The 2019 FIGO classification for cervical carcinoma-what's new?]

Authors:  L-C Horn; C E Brambs; S Opitz; U A Ulrich; A K Höhn
Journal:  Pathologe       Date:  2019-11       Impact factor: 1.011

Review 2.  [Revised German guidelines on the diagnosis and treatment of carcinoma of the uterine cervix-what's new for pathologists in 2021?]

Authors:  Lars-Christian Horn; Matthias W Beckmann; Markus Follmann; Martin C Koch; Monika Nothacker; Birgit Pöschel; Frederik Stübs; Dietmar Schmidt; Anne Kathrin Höhn
Journal:  Pathologie (Heidelb)       Date:  2022-02-21

3.  Invasive stratified mucin-producing carcinoma (ISMC) of uterine cervix: description of pathological findings and prognosis factors in a series of 15 Chinese patients.

Authors:  Ting Lin; Wei Wang; Lian Xu; Ying He
Journal:  Arch Gynecol Obstet       Date:  2022-04-08       Impact factor: 2.493

4.  Invasive Stratified Mucin-producing Carcinoma (ISMC) of the Uterine Cervix: Clinicopathological and Molecular Characteristics With Special Emphasis on the First Description of Consistent Programmed Death-ligand 1 (PD-L1) Over-expression.

Authors:  Sangjoon Choi; So-Woon Kim; Hyun-Soo Kim
Journal:  Cancer Genomics Proteomics       Date:  2021 Sep-Oct       Impact factor: 4.069

5.  Invasive Stratified Mucinous Carcinoma (iSMC) of the Cervix Often Presents With High-risk Features That Are Determinants of Poor Outcome: An International Multicenter Study.

Authors:  Simona Stolnicu; Monica Boros; Sheila Segura; Lars-Christian Horn; Carlos Parra-Herran; Esther Oliva; Nadeem Abu-Rustum; Robert A Soslow; Kay J Park
Journal:  Am J Surg Pathol       Date:  2020-10       Impact factor: 6.298

Review 6.  Grading of Endocervical Adenocarcinomas: Review of the Literature and Recommendations From the International Society of Gynecological Pathologists.

Authors:  Karen L Talia; Esther Oliva; Joseph T Rabban; Naveena Singh; Simona Stolnicu; W Glenn McCluggage
Journal:  Int J Gynecol Pathol       Date:  2021-03-01       Impact factor: 3.326

Review 7.  Tumor Typing of Endocervical Adenocarcinoma: Contemporary Review and Recommendations From the International Society of Gynecological Pathologists.

Authors:  Simona Stolnicu; Kay J Park; Takako Kiyokawa; Esther Oliva; W Glenn McCluggage; Robert A Soslow
Journal:  Int J Gynecol Pathol       Date:  2021-03-01       Impact factor: 3.326

8.  Immunohistochemical and genetic characteristics of HPV-associated endocervical carcinoma with an invasive stratified mucin-producing carcinoma (ISMC) component.

Authors:  Eunhyang Park; Young Tae Kim; Sunghoon Kim; Eun Ji Nam; Nam Hoon Cho
Journal:  Mod Pathol       Date:  2021-06-08       Impact factor: 7.842

9.  Invasive Stratified Mucin-producing Carcinoma (ISMC) of the Cervix: A Study on Morphologic Diversity.

Authors:  Simona Stolnicu; Sheila Segura; Carlos Parra-Herran; Lars-Christian Horn; Lynn Hoang; Cristina Terinte; Anna Pesci; Sarit Aviel-Ronen; Takako Kyokawa; Isabel Alvarado-Cabrero; Esther Oliva; Robert A Soslow; Kay J Park
Journal:  Am J Surg Pathol       Date:  2020-07       Impact factor: 6.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.